Kyverna therapeutics provides business update and reports first quarter 2025 financial results

Enrollment complete in registrational phase 2 kyv-101 trial in stiff person syndrome (sps); on track for topline data in 1h 2026; biologics license application (bla) filing now anticipated in 1h 2026  advancing into registrational phase 3 kyv-101 trial in myasthenia gravis (mg) following successful end-of-phase 2 meeting with u.s. food and drug administration (fda); phase 2 mg data anticipated in 2h 2025 company to host kol event in q3 2025, spotlighting its accelerating neuroinflammation franchise  strong financial position; cash runway into 2027 supports first bla filing, mg phase 3 trial and pre-launch activities  emeryville, calif. , may 13, 2025 /prnewswire/ -- kyverna therapeutics, inc. (nasdaq: kytx), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the quarter ended march 31, 2025.
KYTX Ratings Summary
KYTX Quant Ranking